GOSS
Price
$1.25
Change
-$0.05 (-3.85%)
Updated
Jun 27 closing price
Capitalization
281.85M
44 days until earnings call
IONS
Price
$39.78
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
6.33B
32 days until earnings call
Interact to see
Advertisement

GOSS vs IONS

Header iconGOSS vs IONS Comparison
Open Charts GOSS vs IONSBanner chart's image
Gossamer Bio
Price$1.25
Change-$0.05 (-3.85%)
Volume$26.07M
Capitalization281.85M
Ionis Pharmaceuticals
Price$39.78
Change-$0.00 (-0.00%)
Volume$2.48M
Capitalization6.33B
GOSS vs IONS Comparison Chart in %
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. IONS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and IONS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GOSS: $1.25 vs. IONS: $39.78)
Brand notoriety: GOSS and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 1262% vs. IONS: 155%
Market capitalization -- GOSS: $281.85M vs. IONS: $6.33B
GOSS [@Biotechnology] is valued at $281.85M. IONS’s [@Biotechnology] market capitalization is $6.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, GOSS is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 2 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • GOSS’s TA Score: 2 bullish, 6 bearish.
  • IONS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, IONS is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а -13.19% price change this week, while IONS (@Biotechnology) price change was +6.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GOSS is expected to report earnings on Aug 12, 2025.

IONS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.34B) has a higher market cap than GOSS($282M). GOSS YTD gains are higher at: 38.183 vs. IONS (13.787). GOSS has higher annual earnings (EBITDA): -35.7M vs. IONS (-357.21M). IONS has more cash in the bank: 2.15B vs. GOSS (258M). GOSS has less debt than IONS: GOSS (203M) vs IONS (1.41B). IONS has higher revenues than GOSS: IONS (717M) vs GOSS (125M).
GOSSIONSGOSS / IONS
Capitalization282M6.34B4%
EBITDA-35.7M-357.21M10%
Gain YTD38.18313.787277%
P/E RatioN/AN/A-
Revenue125M717M17%
Total Cash258M2.15B12%
Total Debt203M1.41B14%
FUNDAMENTALS RATINGS
GOSS vs IONS: Fundamental Ratings
GOSS
IONS
OUTLOOK RATING
1..100
5338
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4242
P/E GROWTH RATING
1..100
10067
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (60) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (96) in the Biotechnology industry. This means that GOSS’s stock grew somewhat faster than IONS’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as IONS (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to IONS’s over the last 12 months.

IONS's SMR Rating (98) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that IONS’s stock grew similarly to GOSS’s over the last 12 months.

IONS's Price Growth Rating (42) in the Biotechnology industry is in the same range as GOSS (42) in the Pharmaceuticals Major industry. This means that IONS’s stock grew similarly to GOSS’s over the last 12 months.

IONS's P/E Growth Rating (67) in the Biotechnology industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that IONS’s stock grew somewhat faster than GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSIONS
RSI
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
65%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
69%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 10 days ago
61%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 14 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IIIIX13.030.11
+0.85%
Voya International Index Port I
CWMCX62.830.27
+0.43%
American Funds Washington Mutual 529C
GSRLX12.510.05
+0.37%
Goldman Sachs Rising Dividend Gr Instl
SFSLX26.290.08
+0.31%
1919 Financial Services C
JFNNX65.76-0.09
-0.14%
Janus Henderson Global Life Sciences N

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
N/A
ALNY - IONS
57%
Loosely correlated
+1.55%
IDYA - IONS
50%
Loosely correlated
-4.13%
ARWR - IONS
48%
Loosely correlated
+0.06%
IMVT - IONS
48%
Loosely correlated
N/A
BEAM - IONS
48%
Loosely correlated
-1.98%
More